Artificial Antigen Presenting Cells for Immune Checkpoint Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing the effectiveness of antibodies against immune checkpoint receptors are costly, time-consuming, and prone to variability, particularly in measuring the inhibition of immune checkpoint pathways in cancer treatment.
Innovation Solution
The use of artificial antigen presenting cells (aAPCs) and immune effector cells, which display T cell receptor activators and immune checkpoint ligands, to assess the potency of test agents in inhibiting immune checkpoints through the formation of immune checkpoint receptor/ligand complexes and subsequent modulation of T cell activation pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional animal models are used to assess antitumor effects of mAb blockage, then phenotypic analysis of tumor masses and survival rates can be obtained, but the process becomes cost and time prohibitive
Solution Approach 1:
The patent uses artificial antigen presenting cells (aAPCs) that replicate the functional characteristics of natural APCs in a simplified, controlled system. These aAPCs display immune checkpoint ligands and co-stimulatory molecules, allowing T cell activation and checkpoint pathway assessment without requiring live animal models or complex in vivo tumor assays, thus reducing time and cost while maintaining measurement precision.
Solution Approach 2:
The patent segments the complex immune checkpoint assessment into discrete, measurable components by using aAPCs with specific surface markers (immune checkpoint ligands and co-stimulatory molecules) that can be individually controlled and measured. This allows isolated assessment of checkpoint pathway effects on T cell activation without the confounding variables of whole animal systems.
2Measurement precision
If freshly isolated peripheral blood mononuclear cells (PBMC) are used to study immunotherapy drugs, then cytokine production can be measured, but isolation is tedious and results show great variability
Solution Approach 1:
The patent creates artificial antigen presenting cells that replicate the essential functions of natural PBMCs in a controlled, reproducible system. The aAPCs are engineered with consistent surface expression of immune checkpoint ligands and co-stimulatory molecules, eliminating the variability inherent in isolating and culturing human PBMCs while maintaining the ability to measure cytokine production and T cell activation.
Solution Approach 2:
The patent standardizes the parameters of the antigen presenting cells by using aAPCs with controlled surface marker expression levels and consistent cellular characteristics. This parameter standardization eliminates the variability between different PBMC isolates and enables reproducible, high-precision measurements of immunotherapy drug effects on cytokine production.
3Measurement precision
If cell-based assays measuring IL-2 production in Jurkat cells are used, then immune checkpoint receptor inhibition can be assessed, but a minimum of two days is required after antibody stimulation
Solution Approach 1:
The patent pre-engages T cells with aAPCs displaying immune checkpoint ligands and co-stimulatory molecules before adding the test antibody. This preliminary setup allows the assay to directly measure the immediate effect of the antibody on the pre-formed immune synapse, eliminating the need for extended incubation periods required by traditional Jurkat cell assays to observe IL-2 production.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided herein are compositions, systems, and methods for assessing modulators of immune checkpoints. In particular, artificial antigen presenting cells (aAPCs) and immune effector cells are provided to assess the potency of test agents to inhibit immune checkpoints.